Valuation: Veritas In Silico Inc.

Market Cap 2.82B 17.37M 15.18M 14.04M 12.88M 24.39M 1.67B 24.81M 167M 65.78M 817M 65.23M 63.8M P/E 2024
-23.8x
P/E 2025 -7.32x
Enterprise Value 997M 6.14M 5.36M 4.96M 4.55M 8.61M 591M 8.76M 59.15M 23.23M 289M 23.04M 22.53M EV / Sales 2024
18.2x
EV / Sales 2025 14.1x
Free-Float
49.81%
Yield 2024 *
-
Yield 2025 -
05-11 SpiroChem AG and Veritas in Silico Inc. Enter Joint Research Agreement to Initiate Discovery of Next Generation mRNA Binding Chemical Matter CI
04-13 Veritas In Silico and Takeda Mutually Terminate mRNA-Targeted Drug Research Collaboration MT
04-13 Veritas in Silico Inc. Terminates Collaborative Drug Discovery Research with Takeda Pharmaceutical Company Limited CI
02-11 Veritas in Silico Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2026 CI
02-11 Veritas In Silico Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-26 SpiroChem AG and Veritas In Silico Inc. Sign MoU to Accelerate Discovery of Next Generation RNA Binding Chemical Matter CI
01-19 The Jikei University School of Medicine and Veritas In Silico Inc. Announce Patent Publication for Novel Nucleic Acid Therapeutic Targeting Amyotrophic Lateral Sclerosis CI
01-19 Japan Shares Start Week in Red as Trump Threatens More Tariffs on Europe MT
01-19 Veritas In Silico, Jikei University Patent ALS Nucleic Acid Therapy MT
12-22 Veritas In Silico Files Patent for mRNA-Targeted Kidney Injury Drug MT
12-15 Veritas in Silico, Inc. Announces Completion of Patent Examination and Patent Grant Procedures for Drug Delivery System "Perfusio" CI
11-17 Veritas In Silico Partners with Shimane University to Develop Novel Lung Transplant Drug MT
11-17 Veritas In Silico Inc. Announces Start of Joint Research Project with Shimane University Aimed at Developing Novel Drugs to Suppress Post-Lung Transplant Dysfunction CI
1 day-3.91%
1 week-4.35%
Current month-3.02%
1 month+1.46%
3 months-15.56%
6 months-25.09%
Current year-12.92%
1 week 405
Extreme 405
443
1 month 400
Extreme 400
443
Current year 390
Extreme 390
586
1 year 390
Extreme 390
940
3 years 390
Extreme 390
3,475
5 years 390
Extreme 390
3,475
10 years 390
Extreme 390
3,475
Manager TitleAgeSince
Chief Executive Officer 54 2016-11-16
Director of Finance/CFO 57 2021-12-31
Corporate Officer/Principal 69 2018-11-30
Director TitleAgeSince
Director/Board Member 54 2016-11-16
Director/Board Member 59 2019-07-31
Director/Board Member 57 2024-02-29
Change 5-day change 1-year change 3-year change Capi.($)
-3.91%-4.35%-38.44% - 17.37M
-0.54%-2.42%+0.32%+5.65% 49.7B
-2.85%-6.25%+366.61%+572.09% 38.09B
+1.98%+4.82%+13.71%+61.68% 35.29B
+1.78%+0.73%+32.68%-4.80% 35.13B
+0.06%+1.56%+4.41%+27.42% 27.22B
-3.27%-5.67% - - 16.14B
+1.64%+0.45%+70.86%+121.18% 15.36B
+1.58%+2.38%+16.42%+20.19% 13.89B
-1.21%+0.73%+18.02%-30.96% 13.02B
Average -0.94%-0.25%+53.84%+96.56% 24.39B
Weighted average by Cap. -0.77%-0.64%+75.90%+116.67%

Financials

2024 2025
Net sales 195M 1.2M 1.05M 969K 889K 1.68M 115M 1.71M 11.55M 4.54M 56.38M 4.5M 4.4M 91.14M 561K 490K 454K 416K 788K 54.06M 801K 5.41M 2.12M 26.4M 2.11M 2.06M
Net income -236M -1.46M -1.27M -1.18M -1.08M -2.04M -140M -2.08M -14.03M -5.51M -68.49M -5.47M -5.35M -426M -2.62M -2.29M -2.12M -1.94M -3.68M -252M -3.74M -25.26M -9.92M -123M -9.84M -9.62M
Net Debt -2.17B -13.38M -11.69M -10.81M -9.92M -18.78M -1.29B -19.11M -129M -50.66M -630M -50.24M -49.14M -1.83B -11.24M -9.82M -9.08M -8.33M -15.77M -1.08B -16.05M -108M -42.55M -529M -42.19M -41.27M
Logo Veritas In Silico Inc.
Veritas In Silico Inc is a Japan-based company primarily engaged in the pharmaceutical discovery platform business. The main business is small molecule drug discovery targeting messenger ribonucleic acid (mRNA) using the ibVIS platform, which integrates digital technology including in silico ribonucleic acid (RNA) structural analysis technology and drug discovery technology, through joint drug discovery research with pharmaceutical companies to create mRNA-targeted small molecule drugs.
Employees
19
Date Price Change Volume
26-07-17 JP¥418.00 -3.91% 19,200
26-07-16 JP¥435.00 0.00% 2,200
26-07-15 JP¥435.00 +4.32% 10,700
26-07-14 JP¥417.00 -2.11% 6,200
26-07-13 JP¥426.00 -2.52% 4,600
  1. Stock Market
  2. Stocks
  3. 130A Stock